PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.00
D/E of 0.00 while CRVO has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
3.47
Net debt less than half of CRVO's 12.71. Charlie Munger would approve but verify if excess conservatism is warranted given competitive dynamics.
-4767.88
Negative coverage while CRVO shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
8.59
Current ratio 1.25-1.5x CRVO's 6.94. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.